Psychiatry · Belmont, NC
NPI
1740262161
Since 2005
Specialty
Psychiatry
Code 2084P0800X
Group practices
1
Medicare group memberships
Hospitals
0
Hospital affiliations
100 Glenway St, Suite A
Belmont, NC, 28012
Phone (704) 825-2599
Groups this clinician bills Medicare through
Medicare paid
-
No Medicare services published
Medicare patients
-
Drug cost, 2024
$935K
1,815 prescriptions
Company payments, 2025
$1,874
From 9 companies
Medicare prescription drug claims, 2024
In 2024, the drug Joseph L Godfrey prescribed most often to Medicare patients was Benztropine Mesylate, with 105 prescriptions and refills. In total Joseph L Godfrey wrote 1,815 Medicare prescriptions that cost $935K.
| Drug |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2017-02-16.
| Claims |
|---|
| 30-day fills |
|---|
| Patients |
|---|
| Cost |
|---|
| Benztropine Mesylate Generic | 105 | 113 | 21 | $1,158 |
| Cyproheptadine Hcl Generic | 90 | 96 | 15 | $2,909 |
| Propranolol Hcl Generic | 69 | 73 | 11 | $704 |
| Trazodone Hcl Generic | 67 | 69 | 18 | $411 |
| Lurasidone Hcl Generic | 64 | 64 | Under 11 | $11K |
| Invega Sustenna Paliperidone Palmitate | 59 | 59 | 11 | $214K |
| Mirtazapine Generic | 58 | 60 | 11 | $729 |
| Lamotrigine Generic | 56 | 60 | 11 | $572 |
| Quetiapine Fumarate Generic | 54 | 54 | Under 11 | $809 |
| Propranolol Hcl Er Propranolol Hcl | 52 | 58 | Under 11 | $656 |
| Gabapentin Generic | 50 | 50 | Under 11 | $973 |
| Bupropion Xl Bupropion Hcl | 46 | 46 | Under 11 | $922 |
| Abilify Maintena Aripiprazole | 45 | 45 | Under 11 | $128K |
| Vraylar Cariprazine Hcl | 44 | 44 | Under 11 | $63K |
| Escitalopram Oxalate Generic | 43 | 44 | Under 11 | $357 |
Brand drugs: 338 claims; generic drugs: 1,477 claims.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Joseph L Godfrey $1,874 ($1,874 in general payments such as food, travel and fees) from 9 companies. The largest payer was ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) with $691.
| Company | Payments | Amount |
|---|---|---|
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) JNJ | 17 | $691 |
| E.R. Squibb & Sons, L.L.C. BMY | 13 | $249 |
| Neurocrine BioSciences, Inc. NBIX | 12 | $247 |
| Alkermes, Inc. ALKS | 11 | $241 |
| Otsuka America Pharmaceutical, Inc. 4578.T | 14 | $202 |
| Teva Pharmaceuticals USA, Inc. TEVA | 7 | $112 |
| Janssen Pharmaceuticals, Inc JNJ | 4 | $62.24 |
| Abbvie Inc. ABBV | 4 | $61.86 |
| Corium, LLC | 1 | $7.41 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.